Gland Pharma on Tuesday said it had entered into an agreement with Russian Direct Investment Fund (RDIF) to supply up to 252 million doses of COVID-19 vaccine Sputnik V.
The firm said this is the first of multiple partnerships being explored to leverage its manufacturing capabilities to support global supply of the COVID-19 vaccine.
Gland will utilise the Drug Substance and Drug Product facilities at its sites in Hyderabad.
The production is expected to commence from the third quarter of 2021 for estimated delivery starting from fourth quarter of 2021.
Gland Pharma said, under the terms of the agreement, it will first undertake technology transfer of the drug substance to the company’s manufacturing facilities. On successful technology transfer, it will begin manufacturing of drug substance and drug product filling into vials under aseptic conditions.
“Gland Pharma’s expertise in manufacturing of sterile injectable at significant scale will support in establishing a stable supply of COVID-19 vaccine,” a statement said.
In India, Dr. Reddy’s, with whom RDIF has entered into a partnership for clinical trials and markets, had last month applied for emergency use authorisation. An expert committee directed the firm to submit more data. Gland Pharma shares gained 6.95% on Tuesday to close at ₹2718.65.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
